Risks relating to the grant and continued use of core patents and claims by third parties
First written in FY2016. 3 of 7 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「However, if the Company infringes patents or other rights held by another company that it was unable to identify in advance and unexpected litigation or other proceedings arise with a third party, this may affect the Company's business strategy and performance.」
The Company reconfirms the risk of unexpected infringement of third-party patents and litigation, together with preventive measures based on patent searches. - FY2020RestatedAnnual report
「However, if the Company infringes patents or other rights held by another company that it was unable to identify in advance and unexpected litigation or other proceedings arise with a third party, this may affect the Company's business strategy and performance.」
While pursuing preventive measures through patent searches, the Company reconfirms the risk of infringing third-party patents and becoming involved in unexpected litigation or other proceedings. - FY2019RestatedAnnual report
「As of the end of March 2019, there had been no litigation or claims involving third parties concerning patents or other intellectual property rights related to the Group's business.」
The Company reconfirms that there have been no lawsuits or claims by third parties and that it believes the likelihood of a material impediment resulting from patent infringement is low. - FY2017SoftenedAnnual report
「As of the end of March 2017, there had been no litigation or claims involving third parties concerning patents or other intellectual property rights related to the Group's business. The Company believes that the likelihood of a material impediment to its business resulting from infringement of patents or other rights held by other companies is low.」
While the risk relating to the grant and continued use of core patents remains, the Company states that there have been no lawsuits or claims by third parties and that it believes the likelihood of a material impediment resulting from infringement is low. - FY2017-Q3AdvancedAnnual report
「Meanwhile, a patent concerning oxidative stress-visualizing mice, for which the Company conducts business under an exclusive license agreement with a public research institution, was granted in Japan in July last year, while a patent concerning antibodies against a novel lung cancer marker and their diagnostic applications, for which the Company had jointly filed an application with a public research institution, was granted in the United States in December last year.」
In addition to the grant in Japan of the patent concerning oxidative stress-visualizing mice, the patent concerning antibodies against a novel lung cancer marker and their diagnostic applications was granted in the United States. These are specific intellectual-property developments, but the disclosure does not state that all risks relating to core patents or claims by third parties have been eliminated. - FY2017-Q2Related patent grantedAnnual report
「A patent concerning oxidative stress-visualizing mice, for which the Company conducts business under an exclusive license agreement with a public research institution, was granted in Japan in July of this year.」
The Company reports the intellectual-property development consisting of the grant of a Japanese patent concerning oxidative stress-visualizing mice. It does not state that all existing patent-related risks have been eliminated. - FY2016First statedAnnual report
「The possibility cannot be ruled out that the Group may face claims for an injunction against its use of the technology, royalty payments, damages or other relief. If any of these circumstances arises, it could have a material impact on the Company's business.」
The Company identifies risks relating to the grant of patents and claims by third parties concerning the variable gene-trap method and GANP® mouse-related technologies.